Review date set for automated cervical screening:
This article was originally published in Clinica
An FDA panel will meet on January 28 to vote on whether NeoPath's AutoPap system can be sold as a primary screening device for cervical cancer. The company submitted a PMA supplement in August with data on the system's ability to pick out smear slides that do not require manual review. The AutoPath would be the first commercially available automated screening device.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.